This website describes Equisculpt Novem Fund — the brand name of Novem Prime Incorporated VCC Sub-Fund, a sub-fund of the umbrella vehicle Equisculpt Novem Capital VCC, a Mauritius variable capital company holding a Global Business Licence issued by the Financial Services Commission, Mauritius. It is provided for information only and does not constitute an offer, solicitation or investment advice.
The fund is available exclusively to eligible investors who meet applicable qualification requirements, on the basis of its confidential offering documents. It is not open to residents of India under the Indian FEMA and SEBI FPI frameworks, and nothing on this site is directed at any person in a jurisdiction where such distribution would be unlawful.
Past performance — including the track record of related entities — is not indicative of future results. Investment involves risk, including possible loss of capital.
“Alpha is generated during liquidity and ownership transitions — not in fully efficient markets.” The fund concentrates where institutional ownership is still forming: the sub-₹2,000 crore universe and the pre-IPO window before it.
Qualified Institutional Buyer and anchor participation in IPOs, FPOs and public issues — assessed on fundamentals, valuation, governance and post-listing liquidity. Priority allocation with a defined liquidity horizon; valuation and institutional demand are tested at entry.
Listed companies below ₹2,000 crore market value with limited institutional ownership or analyst coverage, showing emerging earnings, governance or liquidity improvements — entered before broad institutional adoption re-rates them.
Selective mid-caps with sustainable earnings growth, strengthening balance sheets and sectoral re-rating catalysts — including threshold plays on increasing FII/DII eligibility. Portfolio balance with upside participation.
Late-stage private companies via pre-IPO placements and unlisted secondary transactions. Negotiated entry valuations — typically at meaningful discounts to expected IPO pricing — with an identifiable liquidity event (IPO, strategic sale or block deal) and a defined holding period of roughly 6–24 months.
Preferential allotments, rights issues, warrants, corporate actions and temporary dislocations caused by non-economic or forced selling — each position evaluated independently on risk-reward asymmetry and exit clarity.
Held to meet quarterly redemption windows and to act when dislocations appear. Strategic allocations sum to 100%; the fund employs no leverage at any level.
Allocation ranges follow the fund’s FSC-authorised investment policy. Actual allocations within these ranges are at the investment manager’s discretion.
The Equisculpt Ventures network: SEBI-registered investment and merchant bankers, direct promoter relationships, and sector-specialist scouts on the ground.
A six-filter quantitative screen — sector and market-cap fit, SEBI compliance validation, and promoter background checks before any diligence spend.
Three-year financial model, legal and regulatory review, industry expert interviews, and on-site management visits.
Investment Committee review against a risk-adjusted return model, entry price negotiation and legal documentation — with a 48-hour decision window when allocation windows open.
Continuous monitoring, quarterly NAV reporting, and execution of the exit identified before deployment — listing, block deal or strategic sale — followed by investor distributions.